Allogene Therapeutics (ALLO) Receivables - Other (2020 - 2025)
Allogene Therapeutics' Receivables - Other history spans 5 years, with the latest figure at $23.5 million for Q3 2025.
- For Q3 2025, Receivables - Other rose 5.16% year-over-year to $23.5 million; the TTM value through Sep 2025 reached $23.5 million, up 5.16%, while the annual FY2024 figure was $20.8 million, N/A changed from the prior year.
- Receivables - Other for Q3 2025 was $23.5 million at Allogene Therapeutics, roughly flat from $23.5 million in the prior quarter.
- Across five years, Receivables - Other topped out at $23.5 million in Q2 2025 and bottomed at $1.2 million in Q1 2023.
- The 5-year median for Receivables - Other is $9.4 million (2022), against an average of $12.1 million.
- The largest annual shift saw Receivables - Other surged 142.86% in 2022 before it tumbled 87.23% in 2023.
- A 5-year view of Receivables - Other shows it stood at $4.1 million in 2021, then tumbled by 63.41% to $1.5 million in 2022, then decreased by 20.0% to $1.2 million in 2023, then soared by 1631.08% to $20.8 million in 2024, then increased by 12.99% to $23.5 million in 2025.
- Per Business Quant, the three most recent readings for ALLO's Receivables - Other are $23.5 million (Q3 2025), $23.5 million (Q2 2025), and $21.6 million (Q1 2025).